L-type calcium currents of human myocytes from ventricle of non-failing and failing hearts and from atrium.
L-type calcium currents were studied in ventricular myocytes isolated from non-failing hearts, i.e. donor hearts not suitable for transplantation, and from severely failing hearts, i.e. explanted hearts of organ recipients, in order to identify possible alterations of the currents in cardiomyopathy. Human atrial myocytes were investigated for comparative purposes. As deficient production of cyclic AMP might contribute to the development of cardiac failure, the responses to forskolin, a direct stimulator of adenylyl cyclase, were also studied. The patch-clamp technique was applied in the single electrode whole-cell mode. Calcium currents were similar in myocytes from non-failing and failing hearts: Maximum current-densities were 3.8 v 3.1 pA/pF, and 2.2 pA/pF in atrial cells. In human ventricular cells, threshold was at -33 mV, maximum at +6 mV and reversal potential at about +50 mV, potentials of half-maximum steady-state inactivation -24 mV and -18 mV. The slopes of steady-state inactivation curves were +4.1 mV in myopathic and +5.5 mV in non-failing cells. In all myocytes the current inactivated with two time constants, a fast one with weak and a slow one with pronounced potential dependency. Ventricular or atrial myocytes from patients pretreated with calcium antagonists and untreated did not differ in current density or steady-state inactivation. Forskolin (0.5 microM) increased calcium currents in myocytes from non-failing and failing hearts to the same extent (by 143 and 150%). While beta-adrenoceptor numbers are reported to decline in severely failing myocardium, our data do not suggest that alterations of the properties of calcium currents contribute to the pathophysiology of heart failure, though the number of investigated hearts is limited due to restricted access to non-failing cardiac tissue. No evidence for impairment of the signal transduction cascade beyond the level of GTP binding proteins was found.
Mewes
T
T
Institut für Pharmakologie, Universität GH Essen, Germany.
Ravens
U
U
D000262:Adenylyl Cyclases / Q000502:physiology; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001692:Biological Transport; D001693:Biological Transport, Active / Q000187:drug effects; D002118:Calcium / Q000502:physiology*; D015220:Calcium Channels / Q000502:physiology; D020746:Calcium Channels, L-Type; D048429:Cell Size; D002675:Child, Preschool; D005576:Colforsin / Q000494:pharmacology; D000242:Cyclic AMP / Q000502:physiology; D015536:Down-Regulation; D005260:Female; D006325:Heart Atria; D006333:Heart Failure / Q000473:pathology / Q000503:physiopathology*; D016027:Heart Transplantation; D006352:Heart Ventricles; D006801:Humans; D008297:Male; D008875:Middle Aged; D009124:Muscle Proteins / Q000502:physiology; D009206:Myocardium / Q000166:cytology*; D018408:Patch-Clamp Techniques; D015398:Signal Transduction; D014019:Tissue Donors
D015220:Calcium Channels; D020746:Calcium Channels, L-Type; D009124:Muscle Proteins; D005576:Colforsin; D000242:Cyclic AMP; D000262:Adenylyl Cyclases; D002118:Calcium